Refractory Acute Myeloid Leukemia (AML) Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Refractory Acute Myeloid Leukemia (AML) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia+9 more
Solu Therapeutics, Inc105 enrolled7 locationsNCT06950034
Recruiting
Phase 2

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute52 enrolled2 locationsNCT06660368
Recruiting
Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 2

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)
Peking University People's Hospital56 enrolled1 locationNCT06869265
Recruiting
Phase 2

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.18 enrolled1 locationNCT05241093
Recruiting
Phase 2

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.15 enrolled1 locationNCT05241106
Recruiting
Phase 1

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)
Nanjing Chia-tai Tianqing Pharmaceutical72 enrolled1 locationNCT06049667